CSIMarket
 


Cryoport inc   (CYRX)
Other Ticker:  
 

Cryoport Inc 's Working Capital Ratio

CYRX's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the forth quarter 2023, Working Capital Ratio fell to 11.77 above Cryoport Inc average.

Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Working Capital Ratio than Cryoport Inc in forth quarter 2023. While Working Capital Ratio total ranking has improved so far during the IV Quarter 2023 to 177, from total ranking in the third quarter 2023 at 364.

Explain Working Capital Ratio
How much in Current Assets CYRX´s has?
What is the value of CYRX´s Current Liabilities?


CYRX Working Capital Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change 24.74 % 21.12 % -0.78 % 2.78 % -5.02 %
Y / Y Current Assets Change -11.3 % -9.71 % -6.44 % -9.13 % -12.85 %
Working Capital Ratio MRQ 11.77 12.27 14.57 14.57 16.55
CYRX's Total Ranking # 177 # 364 # 352 # 375 # 352
Seq. Current Liabilities Change 1.57 % 11.55 % -3.2 % 13.73 % -1.38 %
Seq. Current Assets Change -2.54 % -6.07 % -3.21 % 0.11 % -0.8 %



Working Capital Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 25
Healthcare Sector # 46
Overall Market # 177


Working Capital Ratio Statistics
High Average Low
25.98 8.74 0.24
(Jun 30 2020)   (Jun 30 2013)




Financial Statements
Cryoport Inc 's Current Liabilities $ 46 Millions Visit CYRX's Balance sheet
Cryoport Inc 's Current Assets $ 537 Millions Visit CYRX's Balance sheet
Source of CYRX's Sales Visit CYRX's Sales by Geography


Cumulative Cryoport Inc 's Working Capital Ratio

CYRX's Working Capital Ratio for the trailling 12 Months

CYRX Working Capital Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth 24.74 % 21.12 % -0.78 % 2.78 % -5.02 %
Y / Y Current Assets TTM Growth -11.3 % -9.71 % -6.44 % -9.13 % -12.85 %
Working Capital Ratio TTM 13.23 14.38 15.48 15.71 16.22
Total Ranking TTM # 67 # 2594 # 3112 # 3903 # 162
Seq. Current Liabilities TTM Growth 1.57 % 11.55 % -3.2 % 13.73 % -1.38 %
Seq. Current Assets TTM Growth -2.54 % -6.07 % -3.21 % 0.11 % -0.8 %


On the trailing twelve months basis Due to rise in Current Liabilities in the IV Quarter 2023 to $45.61 millions, cumulative Working Capital Ratio decreased to 13.23 above the CYRX average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Working Capital Ratio than Cryoport Inc . While Working Capital Ratio overall ranking has improved so far to 67, from total ranking during the twelve months ending third quarter 2023 at 2594.

Explain Working Capital Ratio
How much in Current Assets CYRX´s has?
What is the value of CYRX´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 21
Healthcare Sector # 33
Within the Market # 67


trailing twelve months Working Capital Ratio Statistics
High Average Low
19.09 9.05 0.33
(Jun 30 2020)   (Dec. 30, 2014)




Companies with similar Working Capital Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioDec 31 2023 MRQ Current AssetsDec 31 2023 MRQ Current Liabilities
Vistagen Therapeutics Inc   30.76 $ 128.114  Millions$ 4.165  Millions
Morphic Holding inc   28.94 $ 716.928  Millions$ 24.776  Millions
Roivant Sciences Ltd   27.79 $ 6,806.733  Millions$ 244.899  Millions
Lexaria Bioscience Corp   27.22 $ 2.694  Millions$ 0.099  Millions
Belite Bio Inc  24.76 $ 89.940  Millions$ 3.633  Millions
Gh Research Plc  24.49 $ 164.089  Millions$ 6.701  Millions
Astria Therapeutics inc   22.36 $ 250.942  Millions$ 11.221  Millions
Edgewise Therapeutics inc   19.50 $ 326.997  Millions$ 16.771  Millions
Structure Therapeutics Inc   19.14 $ 473.608  Millions$ 24.740  Millions
Protagonist Therapeutics inc   16.71 $ 355.577  Millions$ 21.274  Millions
Royalty Pharma Plc  16.29 $ 1,274.193  Millions$ 78.222  Millions
Lyell Immunopharma Inc   16.07 $ 554.686  Millions$ 34.519  Millions
Agios Pharmaceuticals Inc   15.75 $ 833.835  Millions$ 52.947  Millions
Anixa Biosciences Inc   15.19 $ 25.219  Millions$ 1.660  Millions
Keros Therapeutics Inc   14.25 $ 347.293  Millions$ 24.373  Millions
Compass Pathways Plc  13.33 $ 261.296  Millions$ 19.604  Millions
Vyne Therapeutics Inc   12.73 $ 95.963  Millions$ 7.538  Millions
Rallybio Corporation  12.39 $ 114.789  Millions$ 9.263  Millions
Rezolute Inc   12.00 $ 96.085  Millions$ 8.008  Millions
Immuneering Corporation  11.81 $ 89.084  Millions$ 7.545  Millions
Cryoport inc   11.77 $ 536.792  Millions$ 45.610  Millions
Cassava Sciences Inc  11.62 $ 129.633  Millions$ 11.158  Millions
Virios Therapeutics Inc   11.62 $ 4.165  Millions$ 0.359  Millions
Anaptysbio Inc   11.41 $ 406.835  Millions$ 35.665  Millions
Vanda Pharmaceuticals Inc   11.26 $ 432.946  Millions$ 38.460  Millions
Prothena Corporation Public Limited Company  11.24 $ 639.282  Millions$ 56.891  Millions
Cymabay Therapeutics Inc   10.96 $ 403.802  Millions$ 36.843  Millions
Ovid Therapeutics Inc   10.72 $ 109.598  Millions$ 10.228  Millions
Spyre Therapeutics Inc   10.68 $ 341.528  Millions$ 31.978  Millions
Chimerix Inc   10.25 $ 189.110  Millions$ 18.443  Millions

Date modified: 2024-03-13T23:04:03+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com